25CN-NBOH: A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor

Research output: Contribution to journal › Review › Research › peer-review

Standard

25CN-NBOH : A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor. / Märcher-Rørsted, Emil; Jensen, Anders A.; Kristensen, Jesper Langgaard.

In: ChemMedChem, Vol. 16, No. 21, 2021, p. 3263-3270.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Märcher-Rørsted, E, Jensen, AA & Kristensen, JL 2021, '25CN-NBOH: A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor', ChemMedChem, vol. 16, no. 21, pp. 3263-3270. https://doi.org/10.1002/cmdc.202100395

APA

Märcher-Rørsted, E., Jensen, A. A., & Kristensen, J. L. (2021). 25CN-NBOH: A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor. ChemMedChem, 16(21), 3263-3270. https://doi.org/10.1002/cmdc.202100395

Vancouver

Märcher-Rørsted E, Jensen AA, Kristensen JL. 25CN-NBOH: A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor. ChemMedChem. 2021;16(21):3263-3270. https://doi.org/10.1002/cmdc.202100395

Author

Märcher-Rørsted, Emil ; Jensen, Anders A. ; Kristensen, Jesper Langgaard. / 25CN-NBOH : A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor. In: ChemMedChem. 2021 ; Vol. 16, No. 21. pp. 3263-3270.

Bibtex

@article{2c6e1992259c48e1a72bbd80cfbc0a53,
title = "25CN-NBOH: A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor",
abstract = "4-(2-((2-hydroxybenzyl)amino)ethyl)-2,5-dimethoxybenzonitrile (25CN-NBOH) was first reported as a potent and selective serotonin 2A receptor (5-HT 2A R) agonist in 2014, and it has since found extensive use as a pharmacological tool in a variety of in vitro, ex vivo and in vivo studies. 25CN-NBOH is readily available from a synthetic perspective using standard chemical transformations, and displays favorable physiochemical properties in terms of stability and solubility. Due to its superior selectivity for 5-HT 2A R, 25CN-NBOH has been used to investigate the effects of selective 5-HT 2A R activation in vivo, and has thus become an important pharmacological tool for the exploration of 5-HT 2A R signaling in a range of animal models. In the present review, we outline the discovery of 25CN-NBOH, its pharmacological profile and major findings from studies where it has been used.",
author = "Emil M{\"a}rcher-R{\o}rsted and Jensen, {Anders A.} and Kristensen, {Jesper Langgaard}",
note = "{\textcopyright} 2021 Wiley-VCH GmbH.",
year = "2021",
doi = "10.1002/cmdc.202100395",
language = "English",
volume = "16",
pages = "3263--3270",
journal = "Farmaco",
issn = "1860-7179",
publisher = "Wiley - V C H Verlag GmbH & Co. KGaA",
number = "21",

}

RIS

TY - JOUR

T1 - 25CN-NBOH

T2 - A selective agonist for in vitro and in vivo investigations of the serotonin 2A receptor

AU - Märcher-Rørsted, Emil

AU - Jensen, Anders A.

AU - Kristensen, Jesper Langgaard

N1 - © 2021 Wiley-VCH GmbH.

PY - 2021

Y1 - 2021

N2 - 4-(2-((2-hydroxybenzyl)amino)ethyl)-2,5-dimethoxybenzonitrile (25CN-NBOH) was first reported as a potent and selective serotonin 2A receptor (5-HT 2A R) agonist in 2014, and it has since found extensive use as a pharmacological tool in a variety of in vitro, ex vivo and in vivo studies. 25CN-NBOH is readily available from a synthetic perspective using standard chemical transformations, and displays favorable physiochemical properties in terms of stability and solubility. Due to its superior selectivity for 5-HT 2A R, 25CN-NBOH has been used to investigate the effects of selective 5-HT 2A R activation in vivo, and has thus become an important pharmacological tool for the exploration of 5-HT 2A R signaling in a range of animal models. In the present review, we outline the discovery of 25CN-NBOH, its pharmacological profile and major findings from studies where it has been used.

AB - 4-(2-((2-hydroxybenzyl)amino)ethyl)-2,5-dimethoxybenzonitrile (25CN-NBOH) was first reported as a potent and selective serotonin 2A receptor (5-HT 2A R) agonist in 2014, and it has since found extensive use as a pharmacological tool in a variety of in vitro, ex vivo and in vivo studies. 25CN-NBOH is readily available from a synthetic perspective using standard chemical transformations, and displays favorable physiochemical properties in terms of stability and solubility. Due to its superior selectivity for 5-HT 2A R, 25CN-NBOH has been used to investigate the effects of selective 5-HT 2A R activation in vivo, and has thus become an important pharmacological tool for the exploration of 5-HT 2A R signaling in a range of animal models. In the present review, we outline the discovery of 25CN-NBOH, its pharmacological profile and major findings from studies where it has been used.

U2 - 10.1002/cmdc.202100395

DO - 10.1002/cmdc.202100395

M3 - Review

C2 - 34288515

VL - 16

SP - 3263

EP - 3270

JO - Farmaco

JF - Farmaco

SN - 1860-7179

IS - 21

ER -

ID: 274574827